Q-Med AB, a biotech/medical device company based in Sweden, obtained registration approval in China for Restylane®, its dermal filler. The company will follow up with an application for sales approval, which Q-Med expects will allow launch of the product within six months. Restylane® is a hyaluronic acid injection product, the first to be approved for use in China. More details...

Stock Symbol: (STO: QMED)